The Effect of Sodium–Glucose Cotransporter-2 Inhibitors on COVID-19 Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study Using the Common Data Model
Background: There is no clinical evidence about the effect of sodium–glucose cotransporter-2 (SGLT2) inhibitors on diabetic patients who have been diagnosed with coronavirus disease 19 (COVID-19). Methods: The dataset is based on insurance benefit claims sent to the Health Insurance Review and Asses...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/13/2/431 |
| _version_ | 1797339717183733760 |
|---|---|
| author | Kyoung Ree Lim Kwang Jin Chun Bum Sung Kim Seunghwa Lee |
| author_facet | Kyoung Ree Lim Kwang Jin Chun Bum Sung Kim Seunghwa Lee |
| author_sort | Kyoung Ree Lim |
| collection | DOAJ |
| description | Background: There is no clinical evidence about the effect of sodium–glucose cotransporter-2 (SGLT2) inhibitors on diabetic patients who have been diagnosed with coronavirus disease 19 (COVID-19). Methods: The dataset is based on insurance benefit claims sent to the Health Insurance Review and Assessment Service of Korea from January, 2018 to April, 2022. Among 9,822,577 patients who were involved in the claims, diabetic patients were divided into two groups based on whether they had a prescription for an SGLT2 inhibitor. The primary outcome was major adverse cardiac and cerebrovascular events (MACCEs), which were a composite of all-cause mortality, myocardial infarction, stroke, and revascularization over 90 days. Results: A total of 172,682 patients was analyzed. In the propensity score-matched analysis, the rate of MACCE was lower in the SGLT2 inhibitor group compared to the non-SGLT2 inhibitor group (0.89% vs. 1.31%; hazard ratio, 0.71; 95% confidence interval, 0.53–0.94; <i>p</i> =0.020). Each of the MACCEs showed no differences between the two groups. The rate of pneumonia was similar between the two groups (4.45% vs. 4.39%; hazard ratio, 1.06; 95% confidence interval, 0.91–1.16; <i>p</i> = 0.620). Conclusions: In the diabetic patients who were diagnosed with COVID-19, SGLT2 inhibitors were associated with improved clinical outcomes in terms of MACCEs. SGLT2 inhibitors might be considered for prescription to diabetic patients in the current context of long COVID-19. |
| first_indexed | 2024-03-08T09:52:25Z |
| format | Article |
| id | doaj.art-f54b1d7c970a4025aef807d0eb7d5541 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-08T09:52:25Z |
| publishDate | 2024-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-f54b1d7c970a4025aef807d0eb7d55412024-01-29T14:01:43ZengMDPI AGJournal of Clinical Medicine2077-03832024-01-0113243110.3390/jcm13020431The Effect of Sodium–Glucose Cotransporter-2 Inhibitors on COVID-19 Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study Using the Common Data ModelKyoung Ree Lim0Kwang Jin Chun1Bum Sung Kim2Seunghwa Lee3Division of Infectious Diseases, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Seoul 05278, Republic of KoreaDivision of Cardiology, Department of Internal Medicine, Kangwon National University Hospital, Kangwon National University School of Medicine, Chuncheon 24341, Republic of KoreaDivision of Cardiology, Department of Medicine, Konkuk University Medical Center, Seoul 05029, Republic of KoreaDivision of Cardiology, Department of Medicine, Wiltse Memorial Hospital, Suwon 16480, Republic of KoreaBackground: There is no clinical evidence about the effect of sodium–glucose cotransporter-2 (SGLT2) inhibitors on diabetic patients who have been diagnosed with coronavirus disease 19 (COVID-19). Methods: The dataset is based on insurance benefit claims sent to the Health Insurance Review and Assessment Service of Korea from January, 2018 to April, 2022. Among 9,822,577 patients who were involved in the claims, diabetic patients were divided into two groups based on whether they had a prescription for an SGLT2 inhibitor. The primary outcome was major adverse cardiac and cerebrovascular events (MACCEs), which were a composite of all-cause mortality, myocardial infarction, stroke, and revascularization over 90 days. Results: A total of 172,682 patients was analyzed. In the propensity score-matched analysis, the rate of MACCE was lower in the SGLT2 inhibitor group compared to the non-SGLT2 inhibitor group (0.89% vs. 1.31%; hazard ratio, 0.71; 95% confidence interval, 0.53–0.94; <i>p</i> =0.020). Each of the MACCEs showed no differences between the two groups. The rate of pneumonia was similar between the two groups (4.45% vs. 4.39%; hazard ratio, 1.06; 95% confidence interval, 0.91–1.16; <i>p</i> = 0.620). Conclusions: In the diabetic patients who were diagnosed with COVID-19, SGLT2 inhibitors were associated with improved clinical outcomes in terms of MACCEs. SGLT2 inhibitors might be considered for prescription to diabetic patients in the current context of long COVID-19.https://www.mdpi.com/2077-0383/13/2/431SGLT2 inhibitorCOVID-19MACCE |
| spellingShingle | Kyoung Ree Lim Kwang Jin Chun Bum Sung Kim Seunghwa Lee The Effect of Sodium–Glucose Cotransporter-2 Inhibitors on COVID-19 Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study Using the Common Data Model Journal of Clinical Medicine SGLT2 inhibitor COVID-19 MACCE |
| title | The Effect of Sodium–Glucose Cotransporter-2 Inhibitors on COVID-19 Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study Using the Common Data Model |
| title_full | The Effect of Sodium–Glucose Cotransporter-2 Inhibitors on COVID-19 Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study Using the Common Data Model |
| title_fullStr | The Effect of Sodium–Glucose Cotransporter-2 Inhibitors on COVID-19 Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study Using the Common Data Model |
| title_full_unstemmed | The Effect of Sodium–Glucose Cotransporter-2 Inhibitors on COVID-19 Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study Using the Common Data Model |
| title_short | The Effect of Sodium–Glucose Cotransporter-2 Inhibitors on COVID-19 Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study Using the Common Data Model |
| title_sort | effect of sodium glucose cotransporter 2 inhibitors on covid 19 patients with type 2 diabetes mellitus a retrospective cohort study using the common data model |
| topic | SGLT2 inhibitor COVID-19 MACCE |
| url | https://www.mdpi.com/2077-0383/13/2/431 |
| work_keys_str_mv | AT kyoungreelim theeffectofsodiumglucosecotransporter2inhibitorsoncovid19patientswithtype2diabetesmellitusaretrospectivecohortstudyusingthecommondatamodel AT kwangjinchun theeffectofsodiumglucosecotransporter2inhibitorsoncovid19patientswithtype2diabetesmellitusaretrospectivecohortstudyusingthecommondatamodel AT bumsungkim theeffectofsodiumglucosecotransporter2inhibitorsoncovid19patientswithtype2diabetesmellitusaretrospectivecohortstudyusingthecommondatamodel AT seunghwalee theeffectofsodiumglucosecotransporter2inhibitorsoncovid19patientswithtype2diabetesmellitusaretrospectivecohortstudyusingthecommondatamodel AT kyoungreelim effectofsodiumglucosecotransporter2inhibitorsoncovid19patientswithtype2diabetesmellitusaretrospectivecohortstudyusingthecommondatamodel AT kwangjinchun effectofsodiumglucosecotransporter2inhibitorsoncovid19patientswithtype2diabetesmellitusaretrospectivecohortstudyusingthecommondatamodel AT bumsungkim effectofsodiumglucosecotransporter2inhibitorsoncovid19patientswithtype2diabetesmellitusaretrospectivecohortstudyusingthecommondatamodel AT seunghwalee effectofsodiumglucosecotransporter2inhibitorsoncovid19patientswithtype2diabetesmellitusaretrospectivecohortstudyusingthecommondatamodel |